N-L-Alanyl-L-histidine | 3253-17-6

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-L-Alanyl-L-histidine
• 英文别名: (2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
• CAS: 3253-17-6
• 化学式: C₉H₁₄N₄O₃
• 分子量: 226.23
• InChiKey: XZWXFWBHYRFLEF-IYSWYEEDSA-N

物化性质

• 沸点：
  629.5±55.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S16,S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933290090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

文献信息

• Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols
  申请人：ICI AUSTRALIA LIMITED

  公开号：EP0132392A2

  公开（公告）日：1985-01-30

  The invention concerns a process for the preparation of an a-substituted-a-cyanomethyl alcohol enantiomer of formula 1 wherein the group R1 is an alkenyl, alkynyl, aryl or heteroaryl group by reacting an aldehyde of formula II with hydrogen cyanide in the presence of a cyclic dipeptide enantiomer at a temperature below ambient temperature. The process enables the preparation of compounds of formula I in high yield and high enantiomeric excess. The enantiomers of formula I may be used as intermediates fortheprepara- tion of chiral pyrethroids and chiral arylethanolamines. The invention also embraces cyclic dipeptide enantiomers, processes for the preparation of chiral pyrethroids and chiral arylethanolamines from a-substituted-a-cyanomethyl alcohol enantiomers of formula I and chiral pyrethroids and chiral ethanolamines and the chiral pyrethroids and chiral ethanolamines prepared thereby.

  本发明涉及一种制备式 1 的 a-取代-a-氰基甲醇对映体的工艺，其中基团 R1 是烯基、炔基、芳基或杂芳基。 其中基团 R1 为烯基、炔基、芳基或杂芳基。 在低于环境温度的条件下，在环状二肽对映体存在的情况下，使式 II 的醛与氰化氢反应。 该工艺可制备高产率和高对映体过量的式 I 化合物。式 I 的对映体可用作制备手性拟除虫菊酯和手性芳基乙醇胺的中间体。 本发明还包括环二肽对映体、从式 I 的 a-取代-a-氰基甲醇对映体制备手性拟除虫菊酯和手性芳基乙醇胺的工艺、手性拟除虫菊酯和手性乙醇胺以及由此制备的手性拟除虫菊酯和手性乙醇胺。
• Method for treatment of humoral secretion dysfunctions
  申请人：Metis Healthcare S.r.l.

  公开号：US10646476B2

  公开（公告）日：2020-05-12

  The present invention concerns compositions for the increase in the humoral secretion comprising imidazole peptides or extracts containing them, as well as the use of said compositions for the prevention and/or treatment of secretarial dysfunctions of the body mucosa.

  本发明涉及由咪唑肽或含有咪唑肽的提取物组成的用于增加体液分泌的组合物，以及使用所述组合物预防和/或治疗身体粘膜的分泌功能障碍。
• COMPOSITION COMPRISING ALPHA-LIPOIC ACID AND CARNOSINE FOR TREATING THE PHANTOM LIMB SYNDROME
  申请人：Difass International S.r.l.

  公开号：EP2459185B1

  公开（公告）日：2013-11-27
• COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION
  申请人：METIS HEALTHCARE S.r.I.

  公开号：US20180207134A1

  公开（公告）日：2018-07-26

  The present invention concerns compositions for the increase in the humoral secretion comprising imidazole peptides or extracts containing them, as well as the use of said compositions for the prevention and/or treatment of secretarial dysfunctions of the body mucosa.
• [EN] COMPOSITION WITH IMPROVED ANTIOXIDANT AND ANTIGLYCATING ACTIVITY<br/>[FR] COMPOSITION AYANT UNE ACTIVITÉ ANTI-OXYDANTE ET ANTI-GLYCANTE AMÉLIORÉE
  申请人：DIFASS S A

  公开号：WO2008015535A2

  公开（公告）日：2008-02-07

  [EN] In a first aspect, the present invention refers to a composition for human use comprising at least an effective amount of a-lipoic acid and at least an effective amount of carnosine per daily dosage amount. In a second aspect, the present invention refers to a composition for human use comprising at least an effective amount of zinc and at least an effective amount of carnosine per daily dosage amount. In other aspects, the present invention also refers to a composition for oral use comprising one of said compositions and to a kit comprising a) a liquid phase which is acceptable from the nutritional standpoint, and b) a powder phase, wherein said liquid phase or said powder phase comprise said compositions. Advantageously, such compositions allow to attain an unexpected increase of the antioxidant and antiglycating activity, without inducing undesired side effects, in particular to prevent and/or to reduce the risk of onset, as well as to reduce the impact and/or to assist the treatment of the chronic complications of diabetes.
  [FR] Selon un premier aspect, la présente invention concerne une composition destinée à un usage humain comprenant au moins une quantité efficace d'acide a-lipoïque, et au moins une quantité efficace de carnosine par quantité de dosage quotidienne. Selon un second aspect, la présente invention concerne une composition destinée à un usage humain comprenant au moins une quantité efficace de zinc, et au moins une quantité efficace de carnosine par quantité de dosage quotidienne. Selon d'autres aspects, la présente invention concerne également une composition destinée à un usage oral, comprenant l'une desdites compositions, et un coffret comprenant a) une phase liquide qui est acceptable du point de vue nutritionnel, et b) une phase pulvérulente, ladite phase liquide ou ladite phase pulvérulente comprenant lesdites compositions. De façon avantageuse, de telles compositions permettent de parvenir à une augmentation inattendue de l'activité anti-oxydante et anti-glycante, sans induire d'effets secondaires indésirables, en particulier pour prévenir et/ou réduire le risque d'apparition, ainsi que pour réduire l'impact et/ou faciliter le traitement des complications chroniques du diabète.